FREEPORT, N.Y., Feb. 11 /PRNewswire/ -- New clinical research from AGI Dermatics indicates that L-Ergothioneine (EGT) and its natural receptor, OCTN- 1, are a natural part of the skin’s antioxidant defense and are more effective than idebenone in reducing harmful free radicals in photoaged skin. The data was presented at the Poster Session at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio.
“Prior research confirmed that EGT is more effective than idebenone in suppressing MMP-1 secretions that contribute to photodamaged skin,” said Daniel Yarosh, PhD, President, AGI Dermatics. “This research tells us that EGT and its receptor are active participants in the skin’s natural antioxidant system and have a more significant effect than idebenone in reducing hydroxyl radicals. The findings further underscore the value of EGT in topical skincare formulas that provide benefits in treatment of photoaged skin.”
OCTN-1 (Novel Organic Cation Transporter) was recently identified as the receptor for EGT and responsible for its intracellular accumulation. This study of keratinocytes (NHEK) and fibroblasts (NHDF) indicate that the OCTN-1 protein is readily detectable in both skin cell types and suggest that these cells can uptake, store and utilize EGT.
AGI scientists then looked at the influence of EGT and idebenone on UVA340-induced hydrogen peroxide in human fibroblasts. Results show that NHDF treated with EGT had significantly lower levels of damaging hydroxlyl radicals over a 1-hour period than those treated with idebenone.
AGI Dermatics is the developer of Remergent, a doctor-dispensed skincare line based on the science of DNA repair. L-Ergothioneine, an exclusive and maximized amino acid, is formulated in Remergent Clarifying Concentrate2, Progressive Retinol Complex and Advanced Retinol Therapy.
About AGI Dermatics
AGI Dermatics is the bio-pharmaceutical laboratory that has led research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell- signaling in skin. The company’s application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. www.agiderm.com
CONTACT: Liz Mefford of Rpr Marketing Communications, +1-212-317-1462,
Liz.mefford@rprny.com, for AGI Dermatics
Web site: http://www.agiderm.com/
